Significance of plasma N-terminal pro-brain natriuretic peptide in patients with systemic sclerosis-related pulmonary arterial hypertension

Respiratory Medicine

Volumn 97, Issue 11, 2003, Pages 1230-1236

  Mukerjee, D ^a   Yap, L B ^b   Holmes, A M ^a   Nair, D ^b   Ayrton, P ^b   Black, C M ^a   Coghlan, J G ^b  

^a Centre for Rheumatology   (United Kingdom)

^b ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Cardiac catheterisation; N terminal proBNP; Right ventricular dysfunction; Systemic sclerosis related pulmonary hypertension (SScPAH)

Indexed keywords

BRAIN NATRIURETIC PEPTIDE;

ADULT; AGED; AMINO TERMINAL SEQUENCE; ARTICLE; CARDIOPULMONARY HEMODYNAMICS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; FEMALE; HEART CATHETERIZATION; HEART RIGHT VENTRICLE FUNCTION; HEART VENTRICLE ENDDIASTOLIC PRESSURE; HIGH RISK POPULATION; HUMAN; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; MALE; PATIENT MONITORING; PILOT STUDY; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PULMONARY HYPERTENSION; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; STANDARDIZATION; STATISTICAL SIGNIFICANCE; SYSTEMIC SCLEROSIS; WALKING;

EID: 0242319767     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0954-6111(03)00254-3     Document Type: Article

References (31)

1. Mukoyama M, Nakao K, Saito Y. Increased human brain natriuretic peptide in congestive heart failure. N Engl J Med 1990;313:757-8.
2. Yamamoto K, Burnett JC, Jougasake M. Superiority of brain natriuretic peptide as a humoral marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension 1996;28:989-94.
3. Yasue H, Yoshimura M, Sumida A. Localisation of mechanism of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 1994;90:195-203.
4. Maisel A, Krishnaswamy P, Nowak R. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002;347:161-7.
5. Yoshimura M, Yasue H, Morita E. Haemodynamic renal and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure. Circulation 1991;84:1581-8.
6. Nagaya N, Nishikimi T, Uematsu M, et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 2000;102:865-70.
7. Nagaya N, Nishikimi T, Uematsu M, Satoh T, Kyotani S, Sakamaki F, Kakishita M, Fukushima K, Okano Y, Nakanishi N, Miyatake K, Kangawa K. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. J Cardiol 2001;37(2):110-1.
8. Gibbs JSR. Recommendations on the management of pulmonary hypertension in clinical practice. British Cardiac Society Guidelines and Medical Practice Committee, and approved by the British Thoracic Society and the British Society of Rheumatology. Heart 2001;86(Suppl. 1):I1-13.
9. Coghlan JG, Mukerjee D. The heart and pulmonary vasculature in scleroderma: clinical features and pathobiology. Curr Opin Rheumatol. 2001;13(6):495-9.
10. Rich S, Kaufman E, Levy PS. The effect of high doses of calcium channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992;327:76-81.
11. Mukerjee D, St.George D, Black CM, Coghlan JG. The accuracy of non-invasive techniques in the diagnosis of systemic sclerosis related pulmonary arterial hypertension. ESC 2002 Annual Scientific Meeting, Berlin (abstract 485).
12. Mueller T, Gegenhuber A, Poelz W, Haltmayer M. Elecsys proBNP assay. Basel, Switzerland: Roche Diagnostics, F. Hoffmann-LaRoche Ltd.
13. Remme WJ, Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure. task force for the diagnosis and treatment of chronic heart failure, European Society of Cardiology. Eur Heart J 2001;22:1527-60.
14. Demers C, McKelvie RS, Negassa A, Yusuf S. Reliability, validity, and responsiveness of the six-minute walk test in patients with heart failure. Am Heart J. 2001;142(4): 698-703.
15. LeRoy EC, Black CM, Fleischmajer R, et al. Scleroderma: classification, subsets and pathogenesis. Br J Rheumatol 1988;15:202-5.
16. Sanchez O, Humbert M, Sitbon O, et al. Treatment of pulmonary hypertension secondary to connective tissue diseases. Thorax 1999;54:273-7.
17. Buckley MG, Sethu D, Markandu ND, et al. Plasma concentrations and comparisons of brain natriuretic peptide and atrial, natriuretic peptide in normal subjects, cardiac transplant recipients and patients with dialysis-dependent or dialysis independent chronic renal failure. Clin Sci 1992;83:437-44.
18. Stats Direct: www.statsdirect.com.
19. Nagaya N, Ando M, Oya H, Nakanishi N. Plasma brain natriuretic peptide as a non-invasive marker for efficacy of pulmonary thromboendarterectomy. Ann Thorac Surg 2002;74(1):180-4 (discussion 184).
20. MacGregor AJ, Canavan R, Knight C, Denton CP, Davar J, Coghlan J, Black CM. Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival. Rheumatology (Oxford) 2001;40(4):453-7.
21. Cabanes L, Richard-Thiriez R, Fulla Y, et al. Brain natriuretic peptide blood levels in the differential diagnosis of dyspnea. Chest 2001;120(6):2047-50.
22. Tamura N, Ogawa Y, Chusho H, et al. Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc Natl Acad Sci USA 2000;97(8):4239-44.
23. Ogawa Y, Tamura N, Chusho H, et al. Brain natriuretic peptide appears to act locally as an antifibrotic factor in the heart. Can J Physiol Pharmacol 2001;79(8):723-9.
24. Horio T, Nishikimi T, Yoshihara F. Inhibitory regulation of hypertrophy by endogenous atrial natriuretic peptide in cultured cardiac myocytes. Hypertension 2000;35:19-24.
25. King L, Wilkins MR. Natriuretic peptide receptors and the heart. Heart 2002;87:314-6.
26. Knowles JW, Esposito G, Mao L, et al. Pressure-independent enhancement of cardiac hypertrophy in natriuretic peptide receptor A-deficient mice. Clin Invest 2001; 107(8): 975-84.
27. Kim SZ, Cho KW, Kim SH. Modulation of endocardial natriuretic peptide receptors in right ventricutar hypertrophy. Am J Pediatr (Heart Circ Physiol) 1999;277(6): H2280-9.
28. Higuchi Y, Egashira K, Satoh S. Beneficial effects of a neutral endopeptidase inhibitor on exercise-induced myocardial ischemia in patients with stable effort angina pectoris. Circulation 1996;94(1):729.
29. Elkayam U, Akhter MW, Tummala P, et al. Nesiritide: a new drug for the treatment of decompensated heart failure. J Cardiovasc Pharmacol Ther 2002;7(3):181-211.
30. Krishnaswamy P, Lubien E, Clopton P, et al. Utility of B-natriuretic peptide levels in identifying patients with left ventricular systolic or diastolic dysfunction. Am J, Med 2001;111:274-9.
31. Cheng VL, Krishnaswamy P, Kazanegra R, et al. A rapid bedside test for B-type natriuretic peptide predicts treatment outcomes in patients admitted with decompensated heart failure. J Am Coll Cardiol 2001;37:386-9.